Catalyst continues with anti-addiction drug despite Phase II failure
This article was originally published in Scrip
Executive Summary
Catalyst Pharmaceutical Partners will continue developing its CPP-109 (vigabatrin) anti-addiction drug after reporting that a recent Phase II failure in cocaine addicted patients was likely due to unexpectedly low compliance.